FIGURE 5.

Loss of LRRC8A or LRRC8D reduces survival parameters in patients with HNSCC treated with a chemoradiotherapy regimen. A, OS, progression, locoregional control, and distant metastasis (DM) parameters of patients with at least −1 LRRC8A copy-number loss versus control. B, Comparison of polyA RNA-seq expression data to copy-number loss of LRRC8A. Patients were classified into "low" expression group by the cutoff at around 20 rpkm. C, OS data of high (N = 129) and low (N = 58) LRRC8A-expressing patients defined by the cutoff determined in B. D, Patients were further classified into received cumulative dose groups of below or above 200 mg/m² of cisplatin. E, Correlation analysis of LRRC8A versus LRRC8D expression levels. F, OS, progression, and locoregional control parameters of patients differentially expressing LRRC8D (low N = 61, medium N = 60, high = 60). G, Distant metastasis outcome of patients with low, medium, or high LRRC8D expression. H, Distant metastasis outcome of patients differentially expressing LRRC8D further classified in high cumulative dose (left) and low cumulative dose of cisplatin (right). I, Forest plots displaying the results from CoxPH model fits for OS, PFS, locoregional control, and DM-free survival for the >200 mg/m² of cisplatin or <200 mg/m² of cisplatin treatment groups.